{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:08:49Z","timestamp":1793768929552,"version":"4.6.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>There is increasing evidence that multisystem morbidity in patients with Cushing\u2019s disease (CD) is only partially reversible following treatment. We investigated complications from multiple organs in hospitalized patients with CD compared to patients with nonfunctioning pituitary adenoma (NFPA) after pituitary surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Population-based retrospective cohort study using data from the Swiss Federal Statistical Office between January 2012 and December 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Through 1:5 propensity score matching, we compared hospitalized patients undergoing pituitary surgery for CD or NFPA, addressing demographic differences. The primary composite endpoint included all-cause mortality, major adverse cardiac events (ie, myocardial infarction, unstable angina, heart failure, cardiac arrest, and ischemic stroke), hospitalization for psychiatric disorders, sepsis, severe thromboembolic events, and fractures in need of hospitalization. Secondary endpoints comprised individual components of the primary endpoint and surgical reintervention due to disease persistence or recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After matching, 116 patients with CD (mean age 45.4 years [SD, 14.4], 75.0% female) and 396 with NFPA (47.3 years [14.3], 69.7% female) were included and followed for a median time of 50.0 months (IQR 23.5, 82.0) after pituitary surgery. Cushing\u2019s disease presence was associated with a higher incidence rate of the primary endpoint (40.6 vs 15.7 events per 1000 person-years, hazard ratio [HR] 2.75; 95% CI, 1.54-4.90). Cushing\u2019s disease patients also showed increased hospitalization rates for psychiatric disorders (HR 3.27; 95% CI, 1.59-6.71) and a trend for sepsis (HR 3.15; 95% CI, .95-10.40).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Even after pituitary surgery, CD patients faced a higher hazard of complications, especially psychiatric hospitalizations and sepsis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae069","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T04:52:02Z","timestamp":1719809522000},"page":"97-105","source":"Crossref","is-referenced-by-count":7,"title":["Long-term outcomes in patients with Cushing's disease vs nonfunctioning pituitary adenoma after pituitary surgery: an active-comparator cohort study"],"prefix":"10.1093","volume":"191","author":[{"given":"Sara","family":"Germann","sequence":"first","affiliation":[{"name":"University Department of Medicine, Clinic for Endocrinology, Diabetology, and Metabolism, Kantonsspital Aarau , 5001 Aarau , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4551-8549","authenticated-orcid":false,"given":"Roxana","family":"Wimmer","sequence":"additional","affiliation":[{"name":"University Department of Medicine, Clinic for Endocrinology, Diabetology, and Metabolism, Kantonsspital Aarau , 5001 Aarau , Switzerland"},{"name":"Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau , 5001 Aarau , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahel","family":"Laager","sequence":"additional","affiliation":[{"name":"Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau , 5001 Aarau , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Mueller","sequence":"additional","affiliation":[{"name":"University Department of Medicine, Clinic for Endocrinology, Diabetology, and Metabolism, Kantonsspital Aarau , 5001 Aarau , Switzerland"},{"name":"Faculty of Medicine, University of Basel , 4001 Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schuetz","sequence":"additional","affiliation":[{"name":"University Department of Medicine, Clinic for Endocrinology, Diabetology, and Metabolism, Kantonsspital Aarau , 5001 Aarau , Switzerland"},{"name":"Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau , 5001 Aarau , Switzerland"},{"name":"Faculty of Medicine, University of Basel , 4001 Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kaegi-Braun","sequence":"additional","affiliation":[{"name":"University Department of Medicine, Clinic for Endocrinology, Diabetology, and Metabolism, Kantonsspital Aarau , 5001 Aarau , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-5648","authenticated-orcid":false,"given":"Alexander","family":"Kutz","sequence":"additional","affiliation":[{"name":"Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau , 5001 Aarau , Switzerland"},{"name":"Faculty of Medicine, University of Basel , 4001 Basel , Switzerland"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School , 02120 Boston, MA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"issue":"12","key":"2024073119301803400_lvae069-B1","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1210\/jc.2003-032180","article-title":"Transsphenoidal microsurgery for Cushing\u2019s disease: initial outcome and long-term results","volume":"89","author":"Hammer","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024073119301803400_lvae069-B2","doi-asserted-by":"crossref","first-page":"101521","DOI":"10.1016\/j.beem.2021.101521","article-title":"Epidemiology and mortality of Cushing\u2019s syndrome","volume":"35","author":"Hakami","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"2024073119301803400_lvae069-B3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing\u2019s disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"issue":"1","key":"2024073119301803400_lvae069-B4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12020-016-0984-8","article-title":"Cushing\u2019s disease: the burden of illness","volume":"56","author":"Pivonello","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"2024073119301803400_lvae069-B5","first-page":"117","article-title":"Incidence and late prognosis of Cushing\u2019s syndrome: a population-based study","volume":"86","author":"Lindholm","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024073119301803400_lvae069-B6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing\u2019s disease: an epidemiological approach","volume":"40","author":"Etxabe","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2024073119301803400_lvae069-B7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1210\/jc.2011-2957","article-title":"Outcome of Cushing\u2019s disease following transsphenoidal surgery in a single center over 20 years","volume":"97","author":"Hassan-Smith","year":"2012","journal-title":"J Clin Endocrinol Metabol"},{"issue":"5","key":"2024073119301803400_lvae069-B8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/EJE-13-0569","article-title":"Mortality in Cushing\u2019s syndrome: systematic analysis of a large series with prolonged follow-up","volume":"169","author":"Ntali","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2024073119301803400_lvae069-B9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2265.2011.04124.x","article-title":"Mortality and morbidity in Cushing\u2019s syndrome in New Zealand","volume":"75","author":"Bolland","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2024073119301803400_lvae069-B10","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024073119301803400_lvae069-B11","doi-asserted-by":"crossref","first-page":"dgaa291","DOI":"10.1210\/clinem\/dgaa291","article-title":"Excess morbidity persists in patients with Cushing\u2019s disease during long-term remission: a Swedish nationwide study","volume":"105","author":"Papakokkinou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024073119301803400_lvae069-B12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1210\/jc.2006-2112","article-title":"Mortality in patients treated for Cushing\u2019s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma","volume":"92","author":"Dekkers","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024073119301803400_lvae069-B13","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"8","key":"2024073119301803400_lvae069-B14","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1530\/EC-19-0312","article-title":"Validity of discharge ICD-10 codes in detecting the etiologies of endogenous Cushing\u2019s syndrome","volume":"8","author":"Zhou","year":"2019","journal-title":"Endocr Connect"},{"issue":"9","key":"2024073119301803400_lvae069-B15","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/aje\/kwy078","article-title":"Implications of the propensity score matching paradox in pharmacoepidemiology","volume":"187","author":"Ripollone","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"6","key":"2024073119301803400_lvae069-B16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1210\/jc.2018-02524","article-title":"Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study","volume":"104","author":"Ragnarsson","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024073119301803400_lvae069-B17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejim.2011.10.013","article-title":"Mortality in Cushing\u2019s syndrome: a systematic review and meta-analysis","volume":"23","author":"Graversen","year":"2012","journal-title":"Eur J Intern Med"},{"issue":"6","key":"2024073119301803400_lvae069-B18","doi-asserted-by":"crossref","first-page":"bvac045","DOI":"10.1210\/jendso\/bvac045","article-title":"Increased mortality persists after treatment of Cushing\u2019s disease: a matched nationwide cohort study","volume":"6","author":"Bengtsson","year":"2022","journal-title":"J Endocr Soc"},{"issue":"8","key":"2024073119301803400_lvae069-B19","first-page":"2664","article-title":"Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metabol"},{"issue":"10","key":"2024073119301803400_lvae069-B20","doi-asserted-by":"crossref","first-page":"E129","DOI":"10.1210\/jc.2010-0512","article-title":"Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing\u2019s disease","volume":"95","author":"Tiemensma","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024073119301803400_lvae069-B21","doi-asserted-by":"crossref","first-page":"E1640","DOI":"10.1210\/jc.2012-1945","article-title":"Long-term cognitive impairments and attentional deficits in patients with Cushing\u2019s disease and cortisol-producing adrenal adenoma in remission","volume":"97","author":"Ragnarsson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024073119301803400_lvae069-B22","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1210\/clinem\/dgab079","article-title":"Psychotropic drugs in patients with Cushing\u2019s disease before diagnosis and at long-term follow-up: a nationwide study","volume":"106","author":"Bengtsson","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024073119301803400_lvae069-B23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0090-3019(99)00197-4","article-title":"Cerebral atrophy in Cushing\u2019s disease","volume":"53","author":"Simmons","year":"2000","journal-title":"Surg Neurol"},{"issue":"9","key":"2024073119301803400_lvae069-B24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/0006-3223(92)90079-F","article-title":"Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing\u2019s syndrome","volume":"32","author":"Starkman","year":"1992","journal-title":"Biol Psychiatry"},{"issue":"2","key":"2024073119301803400_lvae069-B25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3171\/2019.10.JNS191400","article-title":"Reversibility of impaired brain structures after transsphenoidal surgery in Cushing\u2019s disease: a longitudinal study based on an artificial intelligence-assisted tool","volume":"134","author":"Hou","year":"2020","journal-title":"J Neurosurg"},{"issue":"5","key":"2024073119301803400_lvae069-B26","first-page":"1949","article-title":"Loss of brain volume in endogenous Cushing\u2019s syndrome and its reversibility after correction of hypercortisolism","volume":"87","author":"Bourdeau","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024073119301803400_lvae069-B27","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12020-007-0033-8","article-title":"Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing\u2019s syndrome","volume":"31","author":"Baykan","year":"2007","journal-title":"Endocrine"},{"issue":"5","key":"2024073119301803400_lvae069-B28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s11102-022-01261-9","article-title":"Hypercoagulability in Cushing\u2019s syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols","volume":"25","author":"Feelders","year":"2022","journal-title":"Pituitary"},{"issue":"4","key":"2024073119301803400_lvae069-B29","doi-asserted-by":"crossref","first-page":"M11","DOI":"10.1530\/EJE-15-0198","article-title":"Adverse effects of glucocorticoids: coagulopathy","volume":"173","author":"Coelho","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2024073119301803400_lvae069-B30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cen.12094","article-title":"Hypercoagulability in Cushing\u2019s syndrome: prevalence, pathogenesis and treatment","volume":"78","author":"van der Pas","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2024073119301803400_lvae069-B31","doi-asserted-by":"crossref","first-page":"bvz033","DOI":"10.1210\/jendso\/bvz033","article-title":"Hypercoagulability in Cushing syndrome, prevalence of thrombotic events: a large, single-center, retrospective study","volume":"4","author":"Suarez","year":"2019","journal-title":"J End Soc"},{"issue":"5","key":"2024073119301803400_lvae069-B32","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1530\/EJE-19-0464","article-title":"High mortality within 90 days of diagnosis in patients with Cushing\u2019s syndrome: results from the ERCUSYN registry","volume":"181","author":"Valassi","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024073119301803400_lvae069-B33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11102-010-0256-1","article-title":"Prophylactic antibiotic trends in transsphenoidal surgery for pituitary lesions","volume":"14","author":"Little","year":"2011","journal-title":"Pituitary"},{"key":"2024073119301803400_lvae069-B34","doi-asserted-by":"crossref","first-page":"i1585","DOI":"10.1136\/bmj.i1585","article-title":"Sepsis: pathophysiology and clinical management","volume":"353","author":"Gotts","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"2024073119301803400_lvae069-B35","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s11102-022-01258-4","article-title":"Cardiovascular health and mortality in Cushing\u2019s disease","volume":"25","author":"Coulden","year":"2022","journal-title":"Pituitary"},{"issue":"1","key":"2024073119301803400_lvae069-B36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1460051","article-title":"Increased risk of osteoporotic fractures in patients with Cushing\u2019s syndrome","volume":"146","author":"Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024073119301803400_lvae069-B37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11102-011-0306-3","article-title":"Spontaneous recovery of bone mass after cure of endogenous hypercortisolism","volume":"15","author":"Randazzo","year":"2012","journal-title":"Pituitary"},{"issue":"3","key":"2024073119301803400_lvae069-B38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2265.1992.tb01437.x","article-title":"Normal bone mineral density following cure of Cushing\u2019s syndrome","volume":"36","author":"Manning","year":"1992","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae069\/58373268\/lvae069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/1\/97\/58674278\/lvae069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/1\/97\/58674278\/lvae069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T02:41:38Z","timestamp":1722480098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/191\/1\/97\/7701848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae069","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,7,1]]}}}